Funder: Johnson & Johnson (Janssen)
Due Dates: June 30, 2026 (Implementation Science RFP, RRMM bispecific antibodies) | July 15, 2026 (Implementation Science RFP, RRMM CAR-T)
Funding Amounts: Up to $275,000 per project; lower-cost projects prioritized; project duration up to 18 months.
Summary: Supports implementation science–driven, independent medical education projects to improve care and outcomes for relapsed/refractory multiple myeloma, focusing on bispecific antibodies or CAR-T therapy.
Key Information: General research projects are not eligible; only CME/CE-embedded implementation science initiatives will be considered.